Is NVCR a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for NVCR (NVCR) rests on New-indication launches (Optune Pax and Lua): The February 2026 U.S. Revenue (FY2025) is ~$655M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: NovoCure remains GAAP unprofitable and depends on new launches converting into durable revenue, which is not guaranteed. Whether NVCR is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
NovoCure Ltd. (Nasdaq: NVCR) is an oncology medical device company built around Tumor Treating Fields (TTFields), a therapy that delivers low-intensity alternating electric fields through wearable arrays to disrupt cancer cell division. Its FDA-approved Optune platform spans Optune Gio for glioblastoma, Optune Lua for metastatic non-small cell lung cancer and malignant pleural mesothelioma, and Optune Pax, approved in February 2026 for locally advanced pancreatic cancer. The company reported full-year 2025 net revenue of about $655 million (up ~8%) with roughly 4,620 active patients on therapy at year-end. The investment picture is a growth-versus-profitability tension. The core glioblastoma business is mature and slower-growing, so the equity story now hinges on newer indications (lung and pancreatic) and international expansion driving the next leg. Management guided 2026 revenue to $690 million to $710 million, but the company still posts GAAP net losses (a $71.1 million loss in Q1 2026, inflated by a one-time share-based-comp charge tied to the Optune Pax approval). Gross margins near 78% and a cash position over $400 million give runway, but the path to sustained profitability depends heavily on adoption of the new launches and clinical readouts in additional tumor types.
What's the case for buying NVCR?
1. New-indication launches (Optune Pax and Lua)
The February 2026 U.S. approval of Optune Pax for locally advanced pancreatic cancer opens a large new addressable market, and early launch metrics were encouraging (hundreds of certified providers and prescriptions within the first weeks). Optune Lua in lung cancer and mesothelioma is also ramping, with revenue roughly doubling year over year off a small base. These launches are the primary growth engine now that glioblastoma is mature.
2. International expansion and reimbursement wins
Ex-U.S. markets and favorable currency drove much of the recent revenue growth, and NovoCure continues to secure national reimbursement coverage in markets such as Spain. Broadening payer coverage across Europe and other regions can lift active-patient counts without requiring new clinical approvals.
3. Margin and cost discipline
Gross margin improved to about 78% in Q1 2026 from 75% a year earlier, helped by lower array costs and better supplier pricing. Continued margin gains, if paired with revenue growth, are the mechanism by which the company could narrow its losses over time.
4. Clinical pipeline in additional tumor types
TTFields is being studied across multiple cancers, and positive readouts (like the PANOVA-3 pancreatic trial that supported Optune Pax) can each unlock a new indication. The pipeline extends the potential runway well beyond the current approved uses if trials succeed.
What are the risks to NVCR?
NovoCure remains GAAP unprofitable and depends on new launches converting into durable revenue, which is not guaranteed. Its Phase 3 TRIDENT trial in newly diagnosed glioblastoma failed to meet its primary overall-survival endpoint, a reminder that clinical bets can disappoint and that the mature glioblastoma base offers limited upside. Reimbursement decisions, physician adoption of an unfamiliar device modality, and competition from drug-based oncology standards of care all create uncertainty. The stock has been volatile, and heavy reliance on a single technology platform concentrates risk. Currency swings that recently helped revenue can also reverse.
How is NVCR valued? (as of July 2026)
Snapshot for NVCR as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (FY2025): ~$655M
- Revenue (Q1 2026): ~$174M (up ~12% YoY)
- 2026 revenue guidance: ~$690M to $710M
- Gross margin (Q1 2026): ~78%
- Net loss (Q1 2026): ~$71M (~$0.62/share)
- Cash & short-term investments: ~$432M (Mar 31, 2026)
- Market cap: ~$1.9B to $2.0B
NovoCure trades as a mid-single-digit-growth medical device company that is still not GAAP profitable, so it is valued more on revenue and future-indication optionality than on earnings. The recent quarterly loss was amplified by a roughly $43 million one-time share-based-comp charge linked to the Optune Pax approval. Over $400 million in cash against modest debt gives operating runway while the newer launches scale.
How do you decide if NVCR is a buy?
Rather than asking whether NVCR is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold NVCR indirectly through an index or sector ETF before adding more.
For the full picture, see the NVCR stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about NVCR against your real portfolio and see your actual exposure before deciding.
The bottom line on NVCR
The bottom line: NVCR's story right now is New-indication launches (Optune Pax and Lua), with revenue (fy2025) at ~$655M. If you believe that narrative continues, the call is about sizing NVCR sensibly and checking overlap with what you own; if you doubt it (the risk: novoCure remains GAAP unprofitable and depends on new launches converting into durable revenue, which is not guaranteed.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around NVCR with Walnut
Use NVCR as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is NVCR a good stock to buy right now?
+
The case for NVCR right now is New-indication launches (Optune Pax and Lua), with revenue (fy2025) at ~$655M. If you believe that thesis holds, NVCR is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is novoCure remains GAAP unprofitable and depends on new launches converting into durable revenue, which is not guaranteed. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does NVCR do?
+
NovoCure Ltd.
What are the main risks of NVCR?
+
NovoCure remains GAAP unprofitable and depends on new launches converting into durable revenue, which is not guaranteed. Its Phase 3 TRIDENT trial in newly diagnosed glioblastoma failed to meet its primary overall-survival endpoint, a reminder that clinical bets can disappoint and that the mature glioblastoma base offers limited upside. Reimbursement decisions, physician adoption of an unfamiliar device modality, and competition from drug-based oncology standards of care all create uncertainty. The stock has been volatile, and heavy reliance on a single technology platform concentrates risk. Currency swings that recently helped revenue can also reverse.
What does NovoCure (NVCR) do?
+
NovoCure is an oncology medical device company that makes Tumor Treating Fields (TTFields) therapy, delivered through wearable Optune devices that use low-intensity alternating electric fields to disrupt cancer cell division. Its approved products treat glioblastoma, lung cancer, mesothelioma, and pancreatic cancer.
Is NVCR profitable?
+
No. NovoCure generates substantial product revenue (about $655 million in 2025) but remains unprofitable on a GAAP basis, reporting a net loss of roughly $71 million in Q1 2026. That quarter's loss was widened by a one-time share-based-compensation charge tied to a product approval.
What are NovoCure's main products?
+
The Optune platform includes Optune Gio for glioblastoma, Optune Lua for metastatic non-small cell lung cancer and malignant pleural mesothelioma, and Optune Pax, approved in February 2026 for locally advanced pancreatic cancer. All deliver the same TTFields technology to different tumor types.
Why is NovoCure's growth accelerating in some areas but not others?
+
The core glioblastoma business is mature and grows slowly, so recent growth is driven by newer launches in lung and pancreatic cancer plus international expansion and reimbursement wins. The Optune Pax pancreatic launch and Optune Lua lung ramp are the key growth engines.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell NVCR; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.